Back to results
US 12,534,512 B2Granted
Human monoclonal antibodies to hantavirus and methods of use therefore
AssigneeVanderbilt University
InventorJames E. Crowe, Jr.
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to antibodies binding to and neutralizing hantavirus and methods for use thereof.
Claims22
A method of detecting a hantavirus infection in a subject comprising:
- (a) contacting a sample from said subject with an antibody or antibody fragment comprising heavy chain complementarity determining region (CDRH1-3) sequences and light chain complementarity determining region (CDRL1-3) sequences comprising SEQ ID NOS:
- 85-87 and 148-150, SEQ ID NOS:
- 88-90 and 151-153, SEQ ID NOS:
- 91-93 and 154-156;
- SEQ ID NOS:
- 94-96 and 157-159;
- SEQ ID NOS:
- 97-99 and 160-162;
- SEQ ID NOS:
- 100-102 and 163-165;
- SEQ ID NOS:
- 103-105 and 166-168;
- SEQ ID NOS:
- 106-108 and 169-171;
- SEQ ID NOS:
- 109-111 and 172-174;
- SEQ ID NOS:
- 112-114 and 175-177;
- SEQ ID NOS:
- 115-117 and 178-180;
- SEQ ID NOS:
- 118-120 and 181-183;
- SEQ ID NOS:
- 121-123 and 184-186;
- SEQ ID NOS:
- 124-126 and 187-189;
- SEQ ID NOS:
- 127-129 and 190-192;
- SEQ ID NOS:
- 130-132 and 193-195;
- SEQ ID NOS:
- 133-135 and 196-198;
- SEQ ID NOS:
- 136-138 and 199-201;
- SEQ ID NOS:
- 142-144 and 205-207;
- SEQ ID NOS:
- 145-147 and 208-210;
- SEQ ID NOS:
- 279-281 and 330-332;
- SEQ ID NOS:
- 282-284 and 333-335;
- SEQ ID NOS:
- 285-287 and 336-338;
- SEQ ID NOS:
- 288-290 and 339-341;
- SEQ ID NOS:
- 291-293 and 342-344;
- SEQ ID NOS:
- 294-296 and 345-347;
- SEQ ID NOS:
- 297-299 and 348-350;
- SEQ ID NOS:
- 300-302 and 351-353;
- SEQ ID NOS:
- 303-305 and 354-356;
- SEQ ID NOS:
- 306-308 and 357-359;
- SEQ ID NOS:
- 309-311 and 360-362;
- SEQ ID NOS:
- 312-314 and 363-365;
- SEQ ID NOS:
- 315-317 and 366-368;
- SEQ ID NOS:
- 318-320 and 369-371;
- SEQ ID NOS:
- 321-323 and 372-374;
- SEQ ID NOS:
- 324-326 and 375-377;
- or SEQ ID NOS:
- 327-329 and 378-380;
- and
- (b) detecting hantavirus in said sample by binding of said antibody or antibody fragment to a hantavirus antigen in said sample.
71 more elements
A method of treating a subject infected with hantavirus, or reducing the likelihood of infection of a subject at risk of contracting hantavirus, comprising delivering to said subject an antibody or antibody fragment comprising heavy chain complementarity determining region (CDRH1-3) sequences and light chain complementarity determining region (CDRL1-3) sequences comprising SEQ ID NOS:
- 85-87 and 148-150, SEQ ID NOS:
- 88-90 and 151-153, SEQ ID NOS:
- 91-93 and 154-156;
- SEQ ID NOS:
- 94-96 and 157-159;
- SEQ ID NOS:
- 97-99 and 160-162;
- SEQ ID NOS:
- 100-102 and 163-165;
- SEQ ID NOS:
- 106-108 and 169-171;
- SEQ ID NOS:
- 109-111 and 172-174;
- SEQ ID NOS:
- 112-114 and 175-177;
- SEQ ID NOS:
- 115-117 and 178-180;
- SEQ ID NOS:
- 118-120 and 181-183;
- SEQ ID NOS:
- 121-123 and 184-186;
- SEQ ID NOS:
- 124-126 and 187-189;
- SEQ ID NOS:
- 127-129 and 190-192;
- SEQ ID NOS:
- 142-144 and 205-207;
- SEQ ID NOS:
- 145-147 and 208-210;
- SEQ ID NOS:
- 279-281 and 330-332;
- SEQ ID NOS:
- 282-284 and 333-335;
- SEQ ID NOS:
- 285-287 and 336-338;
- SEQ ID NOS:
- 288-290 and 339-341;
- SEQ ID NOS:
- 291-293 and 342-344;
- SEQ ID NOS:
- 294-296 and 345-347;
- SEQ ID NOS:
- 297-299 and 348-350;
- SEQ ID NOS:
- 300-302 and 351-353;
- SEQ ID NOS:
- 303-305 and 354-356;
- SEQ ID NOS:
- 306-308 and 357-359;
- SEQ ID NOS:
- 309-311 and 360-362;
- SEQ ID NOS:
- 312-314 and 363-365;
- SEQ ID NOS:
- 315-317 and 366-368;
- or SEQ ID NOS:
- SEQ ID NOS:
- 321-323 and 372-374.
55 more elements
A monoclonal antibody or antigen-binding fragment thereof, wherein the antibody or antibody fragment comprises heavy chain complementarity determining region (CDRH1-3) sequences and light chain complementarity determining region (CDRL1-3) sequences comprising SEQ ID NOS:
- 85-87 and 148-150, SEQ ID NOS:
- 88-90 and 151-153, SEQ ID NOS:
- 91-93 and 154-156;
- SEQ ID NOS:
- 94-96 and 157-159;
- SEQ ID NOS:
- 97-99 and 160-162;
- SEQ ID NOS:
- 100-102 and 163-165;
- SEQ ID NOS:
- 103-105 and 166-168;
- SEQ ID NOS:
- 106-108 and 169-171;
- SEQ ID NOS:
- 109-111 and 172-174;
- SEQ ID NOS:
- 112-114 and 175-177;
- SEQ ID NOS:
- 115-117 and 178-180;
- SEQ ID NOS:
- 118-120 and 181-183;
- SEQ ID NOS:
- 121-123 and 184-186;
- SEQ ID NOS:
- 124-126 and 187-189;
- SEQ ID NOS:
- 127-129 and 190-192;
- SEQ ID NOS:
- 130-132 and 193-195;
- SEQ ID NOS:
- 133-135 and 196-198;
- SEQ ID NOS:
- 136-138 and 199-201;
- SEQ ID NOS:
- 142-144 and 205-207;
- SEQ ID NOS:
- 145-147 and 208-210;
- SEQ ID NOS:
- 279-281 and 330-332;
- SEQ ID NOS:
- 282-284 and 333-335;
- SEQ ID NOS:
- 285-287 and 336-338;
- SEQ ID NOS:
- 288-290 and 339-341;
- SEQ ID NOS:
- 291-293 and 342-344;
- SEQ ID NOS:
- 294-296 and 345-347;
- SEQ ID NOS:
- 297-299 and 348-350;
- SEQ ID NOS:
- 300-302 and 351-353;
- SEQ ID NOS:
- 303-305 and 354-356;
- SEQ ID NOS:
- 306-308 and 357-359;
- SEQ ID NOS:
- 309-311 and 360-362;
- SEQ ID NOS:
- 312-314 and 363-365;
- SEQ ID NOS:
- 315-317 and 366-368;
- SEQ ID NOS:
- 318-320 and 369-371;
- SEQ ID NOS:
- 321-323 and 372-374;
- SEQ ID NOS:
- 324-326 and 375-377;
- or SEQ ID NOS:
- 327-329 and 378-380.
68 more elements
A vaccine formulation comprising one or more expression vectors encoding an antibody or antibody fragment comprising heavy chain complementarity determining region (CDRH1-3) sequences and light chain complementarity determining region (CDRL1-3) sequences comprising SEQ ID NOS:
- 85-87 and 148-150, SEQ ID NOS:
- 88-90 and 151-153, SEQ ID NOS:
- 91-93 and 154-156;
- SEQ ID NOS:
- 94-96 and 157-159;
- SEQ ID NOS:
- 97-99 and 160-162;
- SEQ ID NOS:
- 100-102 and 163-165;
- SEQ ID NOS:
- 106-108 and 169-171;
- SEQ ID NOS:
- 109-111 and 172-174;
- SEQ ID NOS:
- 112-114 and 175-177;
- SEQ ID NOS:
- 115-117 and 178-180;
- SEQ ID NOS:
- 118-120 and 181-183;
- SEQ ID NOS:
- 121-123 and 184-186;
- SEQ ID NOS:
- 124-126 and 187-189;
- SEQ ID NOS:
- 127-129 and 190-192;
- SEQ ID NOS:
- 142-144 and 205-207;
- SEQ ID NOS:
- 145-147 and 208-210;
- SEQ ID NOS:
- 279-281 and 330-332;
- SEQ ID NOS:
- 282-284 and 333-335;
- SEQ ID NOS:
- 285-287 and 336-338;
- SEQ ID NOS:
- 288-290 and 339-341;
- SEQ ID NOS:
- 291-293 and 342-344;
- SEQ ID NOS:
- 294-296 and 345-347;
- SEQ ID NOS:
- 297-299 and 348-350;
- SEQ ID NOS:
- 300-302 and 351-353;
- SEQ ID NOS:
- 303-305 and 354-356;
- SEQ ID NOS:
- 306-308 and 357-359;
- SEQ ID NOS:
- 309-311 and 360-362;
- SEO ID NOS:
- 312-314 and 363-365;
- SEQ ID NOS:
- 315-317 and 366-368;
- or SEQ ID NOS:
- SEQ ID NOS:
- 321-323 and 372-374.
55 more elements
An engineered cell encoding an antibody or antibody fragment, wherein the antibody or antibody fragment comprises heavy chain complementarity determining region (CDRH1-3) sequences and light chain complementarity determining region (CDRL1-3) sequences comprising SEQ ID NOS:
- 85-87 and 148-150, SEQ ID NOS:
- 88-90 and 151-153, SEQ ID NOS:
- 91-93 and 154-156;
- SEQ ID NOS:
- 94-96 and 157-159;
- SEQ ID NOS:
- 97-99 and 160-162;
- SEQ ID NOS:
- 100-102 and 163-165;
- SEQ ID NOS:
- 103-105 and 166-168;
- SEQ ID NOS:
- 106-108 and 169-171;
- SEQ ID NOS:
- 109-111 and 172-174;
- SEQ ID NOS:
- 112-114 and 175-177;
- SEQ ID NOS:
- 115-117 and 178-180;
- SEQ ID NOS:
- 118-120 and 181-183;
- SEQ ID NOS:
- 121-123 and 184-186;
- SEQ ID NOS:
- 124-126 and 187-189;
- SEQ ID NOS:
- 127-129 and 190-192;
- SEQ ID NOS:
- 130-132 and 193-195;
- SEQ ID NOS:
- 133-135 and 196-198;
- SEQ ID NOS:
- 136-138 and 199-201;
- SEQ ID NOS:
- 142-144 and 205-207;
- SEQ ID NOS:
- 145-147 and 208-210;
- SEQ ID NOS:
- 279-281 and 330-332;
- SEQ ID NOS:
- 282-284 and 333-335;
- SEQ ID NOS:
- 285-287 and 336-338;
- SEQ ID NOS:
- 288-290 and 339-341;
- SEQ ID NOS:
- 291-293 and 342-344;
- SEQ ID NOS:
- 294-296 and 345-347;
- SEQ ID NOS:
- 297-299 and 348-350;
- SEQ ID NOS:
- 300-302 and 351-353;
- SEQ ID NOS:
- 303-305 and 354-356;
- SEQ ID NOS:
- 306-308 and 357-359;
- SEQ ID NOS:
- 309-311 and 360-362;
- SEQ ID NOS:
- 312-314 and 363-365;
- SEQ ID NOS:
- 315-317 and 366-368;
- SEQ ID NOS:
- 318-320 and 369-371;
- SEQ ID NOS:
- 321-323 and 372-374;
- SEQ ID NOS:
- 324-326 and 375-377;
- or SEQ ID NOS:
- 327-329 and 378-380.
68 more elements
A vaccine formulation comprising one or more antibodies or antibody fragments comprising heavy chain complementarity determining region (CDRH1-3) sequences and light chain complementarity determining region (CDRL1-3) comprising SEQ ID NOS:
- 85-87 and 148-150, SEQ ID NOS:
- 88-90 and 151-153, SEQ ID NOS:
- 91-93 and 154-156;
- SEQ ID NOS:
- 94-96 and 157-159;
- SEQ ID NOS:
- 97-99 and 160-162;
- SEQ ID NOS:
- 100-102 and 163-165;
- SEQ ID NOS:
- 106-108 and 169-171;
- SEQ ID NOS:
- 109-111 and 172-174;
- SEQ ID NOS:
- 112-114 and 175-177;
- SEQ ID NOS:
- 115-117 and 178-180;
- SEQ ID NOS:
- 118-120 and 181-183;
- SEQ ID NOS:
- 121-123 and 184-186;
- SEQ ID NOS:
- 124-126 and 187-189;
- SEQ ID NOS:
- 127-129 and 190-192;
- SEQ ID NOS:
- 142-144 and 205-207;
- SEQ ID NOS:
- 145-147 and 208-210;
- SEQ ID NOS:
- 279-281 and 330-332;
- SEQ ID NOS:
- 282-284 and 333-335;
- SEQ ID NOS:
- 285-287 and 336-338;
- SEQ ID NOS:
- 288-290 and 339-341;
- SEQ ID NOS:
- 291-293 and 342-344;
- SEQ ID NOS:
- 294-296 and 345-347;
- SEQ ID NOS:
- 297-299 and 348-350;
- SEQ ID NOS:
- 300-302 and 351-353;
- SEQ ID NOS:
- 303-305 and 354-356;
- SEQ ID NOS:
- 306-308 and 357-359;
- SEQ ID NOS:
- 309-311 and 360-362;
- SEQ ID NOS:
- 312-314 and 363-365;
- SEQ ID NOS:
- 315-317 and 366-368;
- or SEQ ID NOS:
- SEQ ID NOS:
- 321-323 and 372-374.
55 more elements
A method of protecting the health of a placenta and/or fetus of a pregnant subject infected with or at risk of infection with hantavirus comprising delivering to said subject an antibody or antibody fragment comprising heavy chain complementarity determining region (CDRH1-3) sequences and light chain complementarity determining region (CDRL1-3) sequences comprising SEQ ID NOS:
- 85-87 and 148-150, SEQ ID NOS:
- 88-90 and 151-153, SEQ ID NOS:
- 91-93 and 154-156;
- SEQ ID NOS:
- 94-96 and 157-159;
- SEQ ID NOS:
- 97-99 and 160-162;
- SEQ ID NOS:
- 100-102 and 163-165;
- SEQ ID NOS:
- 106-108 and 169-171;
- SEQ ID NOS:
- 109-111 and 172-174;
- SEQ ID NOS:
- 112-114 and 175-177;
- SEQ ID NOS:
- 115-117 and 178-180;
- SEQ ID NOS:
- 118-120 and 181-183;
- SEQ ID NOS:
- 121-123 and 184-186;
- SEQ ID NOS:
- 124-126 and 187-189;
- SEQ ID NOS:
- 127-129 and 190-192;
- SEQ ID NOS:
- 142-144 and 205-207;
- SEQ ID NOS:
- 145-147 and 208-210;
- SEQ ID NOS:
- 279-281 and 330-332;
- SEQ ID NOS:
- 282-284 and 333-335;
- SEQ ID NOS:
- 285-287 and 336-338;
- SEQ ID NOS:
- 288-290 and 339-341;
- SEQ ID NOS:
- 291-293 and 342-344;
- SEQ ID NOS:
- 294-296 and 345-347;
- SEQ ID NOS:
- 297-299 and 348-350;
- SEQ ID NOS:
- 300-302 and 351-353;
- SEQ ID NOS:
- 303-305 and 354-356;
- SEQ ID NOS:
- 306-308 and 357-359;
- SEQ ID NOS:
- 309-311 and 360-362;
- SEQ ID NOS:
- 312-314 and 363-365;
- SEQ ID NOS:
- 315-317 and 366-368;
- or SEQ ID NOS:
- SEQ ID NOS:
- 321-323 and 372-374.
55 more elements
A method of determining the antigenic stability, antigen amount, correct antigen conformation and/or correct antigen sequence of a hantavirus antigen comprising:
- (a) contacting a sample comprising said antigen with a first antibody or antibody fragment comprising heavy chain complementarity determining region (CDRH1-3) sequences and light chain complementarity determining region (CDRL1-3) sequences comprising SEQ ID NOS:
- 85-87 and 148-150, SEQ ID NOS:
- 88-90 and 151-153, SEQ ID NOS:
- 91-93 and 154-156;
- SEQ ID NOS:
- 94-96 and 157-159;
- SEQ ID NOS:
- 97-99 and 160-162;
- SEQ ID NOS:
- 100-102 and 163-165;
- SEQ ID NOS:
- 103-105 and 166-168;
- SEQ ID NOS:
- 106-108 and 169-171;
- SEQ ID NOS:
- 109-111 and 172-174;
- SEQ ID NOS:
- 112-114 and 175-177;
- SEQ ID NOS:
- 115-117 and 178-180;
- SEQ ID NOS:
- 118-120 and 181-183;
- SEQ ID NOS:
- 121-123 and 184-186;
- SEQ ID NOS:
- 124-126 and 187-189;
- SEQ ID NOS:
- 127-129 and 190-192;
- SEQ ID NOS:
- 130-132 and 193-195;
- SEQ ID NOS:
- 133-135 and 196-198;
- SEQ ID NOS:
- 136-138 and 199-201;
- SEQ ID NOS:
- 142-144 and 205-207;
- SEQ ID NOS:
- 145-147 and 208-210;
- SEQ ID NOS:
- 279-281 and 330-332;
- SEQ ID NOS:
- 282-284 and 333-335;
- SEQ ID NOS:
- 285-287 and 336-338;
- SEQ ID NOS:
- 288-290 and 339-341;
- SEQ ID NOS:
- 291-293 and 342-344;
- SEQ ID NOS:
- 294-296 and 345-347;
- SEQ ID NOS:
- 297-299 and 348-350;
- SEQ ID NOS:
- 300-302 and 351-353;
- SEQ ID NOS:
- 303-305 and 354-356;
- SEQ ID NOS:
- 306-308 and 357-359;
- SEQ ID NOS:
- 309-311 and 360-362;
- SEQ ID NOS:
- 312-314 and 363-365;
- SEQ ID NOS:
- 315-317 and 366-368;
- SEQ ID NOS:
- 318-320 and 369-371;
- SEQ ID NOS:
- 321-323 and 372-374;
- SEQ ID NOS:
- 324-326 and 375-377;
- or SEQ ID NOS:
- 327-329 and 378-380;
- and
- (b) determining antigenic stability, antigen amount, correct antigen conformation and/or correct antigen sequence of said antigen by detectable binding of said first antibody or antibody fragment to said antigen.
71 more elements
Dependencies are inferred from the claim text.